SCHEMBL945241

SCHEMBL945241

CC(C)(C)OC(=O)CCOCC(COCCC(=O)OC(C)(C)C)(COCCC(=O)OC(C)(C)C)NC(=O)C(F)(F)F

nearest known ligand 0.35

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
CA14 Q9ULX7 1/20 0.35
MLYCD O95822 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL943564 0.79 ALDH1A1 (0.31)
SCHEMBL18736143 0.79 TSHR (0.32)
SCHEMBL20828067 0.79 EPHX2 (0.31)
SCHEMBL14343031 0.78
SCHEMBL20050041 0.76 CA12 (0.31) CA14
SCHEMBL25244137 0.75
SCHEMBL29867869 0.75 TLR2 (0.31)
SCHEMBL18349779 0.75 RECQL (0.39) CA14
SCHEMBL18705408 0.75 TSHR (0.38)
SCHEMBL14900159 0.75 STING1 (0.33)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140023592-A1 SELF COUPLING RECOMBINANT ANTIBODY FUSION PROTEINS RWTH AACHEN (DE) 2014-01-23 US disclosed
EP-2587263-A1 Self coupling recombinant antibody fusion proteins Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) 2013-05-01 EP disclosed
US-20110014216-A1 Drug Transfer Based on Coenzyme A and Acyl Carrier Protein COVALYS BIOSCIENCES AG (CH) 2011-01-20 US disclosed
US-20110014216-A1 Drug Transfer Based on Coenzyme A and Acyl Carrier Protein COVALYS BIOSCIENCES AG (CH) 2011-01-20 US disclosed
US-20110014216-A1 Drug Transfer Based on Coenzyme A and Acyl Carrier Protein COVALYS BIOSCIENCES AG (CH) 2011-01-20 US disclosed
US-20110014196-A1 Drug Transfer into Living Cells COVALYS BIOSCIENCES AG (CH) 2011-01-20 US disclosed
US-20110014196-A1 Drug Transfer into Living Cells COVALYS BIOSCIENCES AG (CH) 2011-01-20 US disclosed
US-20110014196-A1 Drug Transfer into Living Cells COVALYS BIOSCIENCES AG (CH) 2011-01-20 US disclosed
US-20100183516-A1 SELF COUPLING RECOMBINANT ANTIBODY FUSION PROTEINS FRAUNHOFER-GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG E.V. (DE) 2010-07-22 US disclosed
EP-2171456-A2 SELF COUPLING RECOMBINANT ANTIBODY FUSION PROTEINS Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) 2010-04-07 EP disclosed
WO-2009043899-A1 DRUG TRANSFER INTO LIVING CELLS COVALYS BIOSCIENCES AG (CH) 2009-04-09 WO disclosed
WO-2009043899-A1 DRUG TRANSFER INTO LIVING CELLS COVALYS BIOSCIENCES AG (CH) 2009-04-09 WO disclosed
WO-2009043900-A1 DRUG TRANSFER BASED ON COENZYME A AND ACYL CARRIER PROTEIN COVALYS BIOSCIENCES AG (CH) 2009-04-09 WO disclosed
WO-2009013359-A2 SELF COUPLING RECOMBINANT ANTIBODY FUSION PROTEINS FRAUNHOFER GESELLSCHAFT ZUR FÖRDERUNG DER ANGEWANDTEN FORSCHUNG E. V. (DE) 2009-01-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110014196-A1 Drug Transfer into Living Cells TSPO, MPI, ABCB1 CA14 3061/4885MLYCD 372/4885
US-20110014216-A1 Drug Transfer Based on Coenzyme A and Acyl Carrier Protein COASY, ACAT2, ACAT1 CA14 3693/4885MLYCD 260/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.